Global Cell Line Development for Biologics Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Cell Line Development for Biologics Market Insights, Forecast to 2034
Cell line development is a critical step in the production of biologics. Biologics are complex molecules that are produced by living cells, such as proteins, antibodies, and vaccines. To produce biologics in large quantities, scientists need to develop cell lines that can produce these molecules consistently and at high levels.
Market Analysis and InsightsGlobal Cell Line Development for Biologics Market
Global Cell Line Development for Biologics market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Cell Line Development for Biologics industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
The global market for cell line development (CLD) in biologics has experienced substantial growth in recent years due to the increasing demand for biopharmaceutical products, including monoclonal antibodies, vaccines, and other therapeutic proteins. Cell line development is a critical step in the biomanufacturing process, involving the selection, optimization, and production of mammalian cell lines that can efficiently produce biologic drugs. The United States and Canada have a robust biopharmaceutical industry, making North America a major market for cell line development services. European countries have a significant presence in biologics development, with established pharmaceutical companies and research institutions driving demand for cell line development. The Asia-Pacific region is emerging as a key market due to its growing biopharmaceutical sector, increased investment in research and development, and access to skilled scientific talent. The cell line development for biologics market is projected to continue growing as biopharmaceutical companies strive to develop innovative and effective therapies. Technological advancements in automation, genomics, and synthetic biology are expected to further streamline and optimize the cell line development process.
Report Covers
This report presents an overview of global Cell Line Development for Biologics market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Cell Line Development for Biologics market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Lonza
Corning
Sartorius
Thermo Fisher Scientific
Selexis
Beckman Coulter (Danaher )
CYTENA
Molecular Devices
Samsung Biologics
Hera BioLabs
GTP Bioways
Abzena
FyoniBio
Catalent
WuXi Biologics
Segment by Type
CHO Cell Lines
HEK293 Cell Lines
Insect Cell Lines
Monoclonal Antibodies
Recombinant Proteins
Vaccines
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Cell Line Development for Biologics introduction, etc. Cell Line Development for Biologics Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Cell Line Development for Biologics
Chapter 13Methodology and Data Sources adopted by MRAResearch
Market Analysis and InsightsGlobal Cell Line Development for Biologics Market
Global Cell Line Development for Biologics market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Cell Line Development for Biologics industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
The global market for cell line development (CLD) in biologics has experienced substantial growth in recent years due to the increasing demand for biopharmaceutical products, including monoclonal antibodies, vaccines, and other therapeutic proteins. Cell line development is a critical step in the biomanufacturing process, involving the selection, optimization, and production of mammalian cell lines that can efficiently produce biologic drugs. The United States and Canada have a robust biopharmaceutical industry, making North America a major market for cell line development services. European countries have a significant presence in biologics development, with established pharmaceutical companies and research institutions driving demand for cell line development. The Asia-Pacific region is emerging as a key market due to its growing biopharmaceutical sector, increased investment in research and development, and access to skilled scientific talent. The cell line development for biologics market is projected to continue growing as biopharmaceutical companies strive to develop innovative and effective therapies. Technological advancements in automation, genomics, and synthetic biology are expected to further streamline and optimize the cell line development process.
Report Covers
This report presents an overview of global Cell Line Development for Biologics market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Cell Line Development for Biologics market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Lonza
Corning
Sartorius
Thermo Fisher Scientific
Selexis
Beckman Coulter (Danaher )
CYTENA
Molecular Devices
Samsung Biologics
Hera BioLabs
GTP Bioways
Abzena
FyoniBio
Catalent
WuXi Biologics
Segment by Type
CHO Cell Lines
HEK293 Cell Lines
Insect Cell Lines
Segment by Application
Monoclonal Antibodies
Recombinant Proteins
Vaccines
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Cell Line Development for Biologics introduction, etc. Cell Line Development for Biologics Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Cell Line Development for Biologics
Chapter 13Methodology and Data Sources adopted by MRAResearch
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices